

Benzothiazines in Organic Synthesis.  
The Preparation of Enantiomerically  
Pure 4-Substituted Quinolones


Michael Harmata\* and Xuechuan Hong

Department of Chemistry, University of Missouri–Columbia,  
Columbia, Missouri 65203

harmatam@missouri.edu

Received May 3, 2007

## ABSTRACT




3,4-Dihydroquinolin-2(1H)-ones have potential biological and pharmacological significance. Enantiomerically pure benzothiazines, readily available via an intramolecular addition of a sulfoximine-stabilized carbanion to an  $\alpha,\beta$ -unsaturated ester, could be used as templates for making a series of enantiomerically pure 3,4-dihydroquinolin-2(1H)-ones under mild conditions.

Quinolin-2(1H)-ones are ubiquitous structural motifs that can be found in many naturally and non-naturally occurring compounds (Figure 1).<sup>1</sup> Many of these heterocycles possess interesting biological properties and have been developed as drugs that are antibiotics,<sup>1b</sup> HIV-1 reverse transcriptase inhibitors,<sup>1c</sup> NMDA antagonists,<sup>1d</sup> and 5-HT3 receptor antagonists.<sup>1e</sup> Their importance in medicinal chemistry has stimulated considerable attention from organic chemists and encouraged the development of new synthetic pathways to prepare these compounds.

A number of syntheses of quinolin-2(1H)-ones have been reported that rely on radical cyclizations of a secondary amide,<sup>2a,b</sup> solid-phase synthesis,<sup>2c</sup> asymmetric cyclocarbonylation of 2-vinylanilines by palladium<sup>2d–h</sup> or rhodium catalysts,<sup>2i</sup> Friedlander-type methods or Friedel–Crafts cyclization,<sup>2j–l</sup> and multicomponent reactions.<sup>2m</sup> Most of the

syntheses of quinolin-2(1H)-ones give racemic compounds or low enantiomeric excesses under relatively harsh reaction




**Figure 1.** Examples of tetrahydroquinolone-containing natural and non-natural products.

(1) (a) Jones, G. In *Comprehensive Heterocyclic Chemistry II*; Katritzky, A. R.; Rees, C. W.; Scriven, E. F. V., Eds.; Pergamon Press: Oxford, UK, 1996; p 167. (b) Uchida, R.; Imasato, R.; Shiomi, K.; Tomoda, H.; Omura, S. *Org. Lett.* **2005**, *7*, 5701. (c) Patel, M.; McHugh, R. J.; Cordova, B. C.; Klabe, R. M.; Bacheler, L. T.; Erickson-Viitanen, S.; Rodgers, J. D. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 1943. (d) Carling, R. W.; Leeson, P. D.; Moore, K. W.; Smith, J. D.; Moyes, C. R.; Mawer, I. M.; Thomas, S.; Chan, T.; Baker, R.; Foster, A. C.; Grimwood, S.; Kemp, J. A.; Marshall, G. R.; Tricklebank, M. D.; Saywell, K. L. *J. Med. Chem.* **1993**, *36*, 3397. (e) Hayashi, H.; Miwa, Y.; Miki, I.; Ichikawa, S.; Yoda, N.; Ishii, A.; Kono, M.; Suzuki, F. *J. Med. Chem.* **1992**, *35*, 4893.

conditions. The use of radical cyclization to build six-membered rings has some limitations as well, often resulting in very low yields.

We recently reported the stereoselective, intramolecular Michael addition of sulfoximine carbanions to  $\alpha,\beta$ -unsaturated esters as exemplified in Scheme 1.<sup>3</sup> The preparation of



sulfoximine **7** was conducted by using the methodology introduced by Bolm and co-workers.<sup>4</sup> Subsequent treatment of sulfoximine **7** with LDA afforded **8** as a single stereoisomer in high yield. The reaction is stereospecific and offers a way of establishing benzylic stereocenters with high fidelity. We are interested in using these benzothiazines as useful synthons in a variety of ways.

Benzothiazines that we have prepared have been directly converted to indoles,<sup>5a</sup> allylanilines,<sup>5b</sup> 2-alkylanilines,<sup>5b-d</sup> and 2-alkenylanilines.<sup>5e</sup> Further, we have demonstrated that the  $C_2$ -symmetric bis-benzothiazines could be used as chiral ligands in asymmetric allylic alkylations.<sup>5f</sup> We also applied benzothiazines to the total syntheses of (+)-curcuphenol, (+)-curcumene,<sup>6</sup> erogorgiaene,<sup>7</sup> and pseudopteroxazole.<sup>8</sup>

(2) (a) Binot, G.; Zard, S. Z. *Tetrahedron Lett.* **2005**, 46, 7503. (b) Clark, A. J.; Jones, K.; McCarthy, C.; Storey, J. M. D. *Tetrahedron Lett.* **1991**, 3, 2829. (c) Turner, K. L.; Baker, T. M.; Islam, S.; Procter, D. J.; Stefaniak, M. *Org. Lett.* **2006**, 8, 329. (d) Touzani, R.; Alper, H. *J. Mol. Catal. A: Chem.* **2005**, 227, 197. (e) Dong, C.; Alper, H., *Tetrahedron: Asymmetry* **2004**, 15, 35. (f) Okuro, K.; Kai, H.; Alper, H. *Tetrahedron: Asymmetry* **1997**, 8, 2307. (g) El Ali, B.; Okuro, K.; Vasapollo, G.; Alper, H. *J. Am. Chem. Soc.* **1996**, 118, 4264. (h) Manley, P. J.; Bilodeau, M. T. *Org. Lett.* **2004**, 6, 2433. (i) Fujita, K.; Takahashi, Y.; Owaki, M.; Yamamoto K.; Yamaguchi, R. *Org. Lett.* **2004**, 6, 2785. (j) Jones G. In *Comprehensive Heterocyclic Chemistry*; Boulton, A. J., McKillop, A., Eds.; Pergamon Press: Oxford, UK, 1984; Vol. 2 (8). (k) Li, K.; Foresee, L. N.; Tunge, J. A. *J. Org. Chem.* **2005**, 70, 2881. (l) Kadnikov, D. V.; Larock, R. C. *J. Org. Chem.* **2004**, 69, 6772. (m) Marcaccini, S.; Pepino, R.; Pozo, M. C.; Basurto, S.; García-Valverde, M.; Torroba, T. *Tetrahedron Lett.* **2004**, 45, 3999.

(3) Harmata, M.; Hong, X. *J. Am. Chem. Soc.* **2003**, 125, 5754. (4) (a) Bolm, C.; Hildebrand, J. P. *Tetrahedron Lett.* **1998**, 39, 5731. (b) Bolm, C.; Hildebrand, J. P. *J. Org. Chem.* **2000**, 65, 169.

(5) (a) Harmata, M.; Herron, B. F. *Tetrahedron* **1991**, 47, 8855. (b) Harmata, M.; Jones, D. E. *Tetrahedron Lett.* **1995**, 36, 4769. (c) Harmata, M.; Herron, B. F. *Tetrahedron* **1991**, 47, 8855. (d) Harmata, M.; Claassen, R. J., II; Barnes, C. L. *J. Org. Chem.* **1991**, 56, 5059. (e) Harmata, M.; Kahraman, M. *Synthesis* **1994**, 142. (f) Harmata, M.; Ghosh, S. K. *Org. Lett.* **2001**, 3, 3321.


(6) Harmata, M.; Hong, X.; Barnes, C. L. *Tetrahedron Lett.* **2003**, 44, 7261.

(7) Harmata, M.; Hong, X. *Tetrahedron Lett.* **2005**, 46, 3847.

(8) (a) Harmata, M.; Hong, X.; Barnes, C. L. *Org. Lett.* **2004**, 6, 2201.

(b) Harmata, M.; Hong, X. *Org. Lett.* **2005**, 7, 3581.

In our continuing efforts to expand the utility of 2,1-benzothiazine chemistry, we thought that our enantiopure 2,1-benzothiazines<sup>3</sup> would be ideal to construct enantiomerically pure 3,4-dihydroquinolin-2(1*H*)-ones. We anticipated that reductive desulfurization with sodium amalgam would result in a transient metal amide that would condense intramolecularly with the ester functional group to produce a lactam (Scheme 2). Indeed, reductive desulfurization of **9**




would yield 3,4-dihydroquinolin-2(1*H*)-one **10** in a concise and especially straightforward way. Herein we reported the first synthesis of enantiopure 3,4-dihydroquinolin-2(1*H*)-ones under mild conditions.

Our initial evaluation of the reductive desulfurization of benzothiazines was carried out using a simple system (Table 1). Treatment of benzothiazines **11a–d** with excess sodium amalgam in methanol/tetrahydrofuran at room temperature

**Table 1.** Conversion of Benzothiazines **11** to 4-Methyl-3,4-dihydroquinolin-2(1*H*)-ones **12**

entry	benzothiazine	Time (h)	dihydroquinolin-2(1 <i>H</i> )-one	yield (%)
1		12		89
2		14		93
3		14		91
4		14		71
5		15		83
6		13		78

Scheme 3




for several hours resulted in the formation of 4-methyl-3,4-dihydroquinolin-2(1*H*)-ones **12a–d** in excellent yields with high enantiopurity (entries 1–4). Benzothiazines **11e,f** displayed similar reactivity to **11b,c**, giving 4-methyl-3,4-dihydroquinolin-2(1*H*)-ones **12b** and **12c** in 83% and 78% yields, respectively. Enantiomerically pure bis-benzothiazine **15** was prepared as per our published procedures<sup>3</sup> involving the reaction of sulfoximine **14** with LDA. Compound **15** could be reduced and condensed to **16** in 65% yield (Scheme 3).

Our efforts were subsequently directed at metalation of the benzothiazines **11f** and their reaction with electrophiles. The products of such reactions would place substituents other than a methyl group at the 4-position of the 4-alkyl-3,4-dihydroquinolin-2(1*H*)-ones obtained upon reduction (Table 2). In the initial attempt, deprotonation of **11f** with 1.1 equiv of LiHMDS at  $-50^{\circ}\text{C}$  for 1 h followed by reaction with 4.0 equiv of  $\text{CH}_3\text{I}$  for 1 h provided exclusively the product

with the methyl on the  $\alpha$  position of the sulfoximine **11f** in 81% yield as a 16.3:1 mixture of isomers. The mixture of these two isomers of **17a** was treated with Na/Hg to provide 4-ethyl-3,4-dihydroquinolin-2(1*H*)-one **18a** in 63% yield via a reductive desulfurization/condensation process (entry 1).

Encouraged by these preliminary results, we considered applying these methods toward the installation of a range of other groups at the 4-position of the 3,4-dihydroquinolin-2(1*H*)-ones. Pleasingly, a variety of substituents could be installed in good yields. An ethyl, allyl, benzyl, or MEM group could be placed on the  $\alpha$  position of the sulfoximine **11f** with the corresponding electrophiles in 44–83% yields with high diastereoselectivity.<sup>9</sup> As expected, benzothiazines **17b–d** were readily converted to 3,4-dihydroquinolin-2(1*H*)-ones **18b–d** with different substituents at the 4-position. However, benzothiazine **17e** was converted to 4-vinyl-3,4-dihydroquinolin-2(1*H*)-one **18e**, instead. The formation of **18e** could be explained by assuming the formation of a negative charge adjacent to the alkoxy group during the course of the reduction. Elimination of the alkoxy group then resulted in the formation of the vinyl group. A related

**Table 2.** Conversion of Benzothiazine **11f** to 4-Alkyl-3,4-dihydroquinolin-2(1*H*)-ones **18**



entry	RX	product	yield (%) <sup>a</sup>	ratio (17, cis:trans) <sup>a</sup>	time, h	product	yield (%)
1	MeI	<b>17a</b>	80	16.3:1	36	<b>18a</b>	63
2	EtBr	<b>17b</b>	44	28.8:1	72	<b>18b</b>	65
3	allyl bromide	<b>17c</b>	83	5.1:1	48	<b>18c</b>	51
4	benzyl bromide	<b>17d</b>	79	16.4:1	72	<b>18d</b>	60
5	MEM-Cl	<b>17e</b>	48	24.1:1	72	<b>18e</b>	72

<sup>a</sup> Determined by  $^1\text{H}$  NMR analysis of the crude reaction mixture.

**Table 3.** Conversion of Thiazines **19** to Ring-Fused Pyridin-2(1*H*)-ones **20**

entry	thiazine	time (h)	pyridin-2(1 <i>H</i> )-one	yield (%)
1	<b>19a</b>	15	<b>20a</b>	87
2	<b>19b</b>	15	<b>20b</b>	81
3	<b>19c</b>	18	<b>20c</b>	90
4	<b>19d</b>	18	<b>20d</b>	68

sequence to introduce substituted alkenes is a potentially general process.

We were also curious to see if heterocyclic ring-fused thiazines **19a–d** could be used for the synthesis of ring-fused pyridin-2(1*H*)-ones. Gratifyingly, good results were obtained when thiophene, furan, and indole thiazines **19a–d** were treated with a similar reaction sequence (Table 3).

---

(9) Allylation of **11f** resulted in only a 5.1:1 mixture of the isomers of **17c** (entry 3, Table 2).

(10) We are assuming the dihydroquinolones are as enantiomerically pure as the sulfoximine **6**, which is used to prepare the benzothiazine precursors of the quinolones. The resolution of **6** is performed according to Gais<sup>11</sup> and the enantiomeric purity of the sulfoxime is checked by chiral column chromatography. We prepared enantiomerically pure **12a** and compared it to racemic material by chiral HPLC to validate this assumption.

(11) Brandt, J.; Gais, H.-J. *Tetrahedron: Asymmetry* **1997**, 8, 909.

In summary, we have developed a new, convenient route for the synthesis of enantiomerically pure 3,4-dihydroquinolin-2(1*H*)-ones<sup>10,11</sup> under mild conditions. Further investigations regarding the scope of the reaction presented and their application in organic synthesis will be reported in due course.

**Acknowledgment.** This work was supported by the NIH (1R01-AI59000-01A1) to whom we are grateful.

**Supporting Information Available:** Experimental procedures, as well as characterization and copies of proton and carbon spectra for all previously unreported compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL0710358